Insider Selling: Disc Medicine (NASDAQ:IRON) COO Sells $731,123.52 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 8,796 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total transaction of $731,123.52. Following the sale, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at approximately $4,515,410.88. This represents a 13.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Monday, August 24th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The stock was sold at an average price of $82.53, for a total value of $24,759.00.
• On Wednesday, August 12th, Jonathan Yen-Wen Yu sold 804 shares of Disc Medicine stock. The stock was sold at an average price of $82.64, for a total value of $66,442.56.
• On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The shares were sold at an average price of $82.50, for a total value of $8,250.00.
• On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The shares were sold at an average price of $72.50, for a total value of $21,750.00.
• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The stock was sold at an average price of $72.66, for a total value of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The stock was sold at an average price of $69.19, for a total value of $1,287,764.28.

Disc Medicine Stock Down 3.1%

IRON stock opened at $80.03 on Friday. Disc Medicine, Inc. has a 52-week low of $40.00 and a 52-week high of $99.50. The company’s 50 day simple moving average is $76.98 and its 200-day simple moving average is $70.04. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. The firm has a market capitalization of $3.07 billion, a P/E ratio of -12.16 and a beta of 1.00.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($1.71) by $0.17. As a group, equities research analysts anticipate that Disc Medicine, Inc. will post -6.61 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. HC Wainwright upped their price objective on shares of Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wedbush reissued an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a research report on Wednesday, June 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Wall Street Zen lowered Disc Medicine from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Morgan Stanley reissued an “overweight” rating and set a $90.00 price objective on shares of Disc Medicine in a research report on Monday, August 17th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $106.50.

Hedge Funds Weigh In On Disc Medicine

A number of institutional investors and hedge funds have recently bought and sold shares of IRON. California State Teachers Retirement System raised its stake in Disc Medicine by 8,273.0% during the 2nd quarter. California State Teachers Retirement System now owns 2,878,790 shares of the company’s stock valued at $210,555,000 after purchasing an additional 2,844,408 shares during the last quarter. BlackRock Inc. acquired a new stake in Disc Medicine in the 2nd quarter worth $180,502,000. JPMorgan Chase & Co. increased its holdings in shares of Disc Medicine by 110.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after purchasing an additional 828,248 shares during the period. BVF Inc. IL bought a new position in shares of Disc Medicine during the 4th quarter worth about $51,616,000. Finally, Jennison Associates LLC acquired a new position in shares of Disc Medicine during the fourth quarter valued at about $42,252,000. Institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.